Dr.Zhao and his team reveal new mechanisms underlying Stem Cell Educator therapy and open up new avenues to improve the treatment of diabetes in clinics.

The features of platelets have been changed after the treatment with Stem Cell Educator therapy in diabetic patients. Platelets and their released mitochondria display immune tolerance-associated markers that can modulate the proliferation and function of immune cells. Using freshly-isolated human pancreatic islets, ex vivo studies established that platelet-releasing mitochondria can migrate to pancreatic islets and be taken up by islet beta cells, leading to the proliferation and enhancement of islet beta-cell functions. This article has been published at the STEM CELLS Translational Medicine.

Dr.Zhao and his team published four-year follow-up studies demonstrated the long-term safety and clinical efficacy of Stem Cell Educator therapy for the treatment of type 1 diabetes (T1D) and T2D.

Clinical data revealed the long-lasting therapeutic efficacy of Stem Cell Educator (SCE) therapy in T1D and T2D subjects after receiving one treatment with SCE therapy.  Specifically, recent onset T1D patients could achieve normal fasting C-peptide levels and remain completely recovered with no relapse after 4 years. To our knowledge, this is the first long-term clinical study demonstrated that islet β cell function has been completely and safely rescued in these recent onset T1D subjects after controlling the autoimmunity by the SCE therapy. Read more in the article at the STEM CELLS Translational Medicine.

The Ministry of Science and Technology of China funded the Stem Cell Educator Therapy for the Treatment of Children with Type 1 Diabetes.

The Ministry of Science and Technology of China funded the Stem Cell Educator therapy for the treatment of children with type 1 diabetes. This project is an international collaboration between Dr. Yong Zhao at Hackensack University Medical Center (USA) and Dr. Zhiguang Zhou at Central South University (China).  

The FDA-approved clinical trial of Stem Cell Educator therapy is started to treat type 1 diabetic patients at Hackensack University Medical Center.

Stem Cell Educator (SCE) therapy - developed and patented by Dr.Zhao – which uses only autologous mononuclear cells that are externally exposed to cord blood stem cells adhering to the SCE device, has previously been proven safe and effective in Chinese and Spanish subjects for the improvement of Type 1 diabetes (T1D) and other autoimmune diseases. If you are interested to join this trial, please contact Dr.Zhao at Yong.Zhao@HackensackMeridian.org

The Third International Conference on Regenerative Medicine was held at the Vatican City.

This groundbreaking Conference gathered the world’s leading scientists in cell therapy, physicians, ethicists and leaders of faith, legislators, and philanthropists to discuss the latest cellular therapy breakthroughs in cancer, diabetes, autoimmune diseases, and rare diseases. The Pope Francis and the American Vice President Biden gave encouraging speeches respectively on the significance of cellular therapy and building up the international collaborations. Dr.Zhao presented the Phase II clinical data on the Stem Cell Educator therapy in type 1 diabetes.  

Media story:

WCBS 2 - Dr. Max Gomez - Diabetes Research Dr. Yong Zhao and Dr. Andrew Pecora (skip to 1:22)

Conference presentation:

Cellular Horizons Day 1 - Cell Therapy Research Discussion for Type 1 Diabetes (skip to 23:43)

 

Dr. Zhao to present research and technology in the Vatican City

Dr.Yong Zhao is invited to attend the Third International Conference on Regenerative Medicine (The Vatican, April 28-30, 2016).This exclusive international event will gather the world’s leading cell therapy scientists, physicians, ethicists and leaders of faith, government and philanthropy to discuss the latest cellular therapy breakthroughs in Cancer, Diabetes and Autoimmune Diseases.

Event:

http://celltherapyconference2016.com/

Bio:

http://celltherapyconference2016.com/2015/11/19/yong-zhao-md-phd/

New alopecia areata trial published in BMC Medicine

A new Phase I/II clinical trial in autoimmune disease alopecia areata has been published in BMC Medicine, titled "Hair Regrowth in Alopecia Areata Patients Following Stem Cell Educator Therapy". Findings from this trial provide visible evidence that Stem Cell Educator therapy can control the autoimmunity and lead to hair regrowth.  

http://www.biomedcentral.com/1741-7015/13/87